Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01723397 · ClinicalTrials.gov registry record · NA
Effect of Nasaleze on Nasal Challenge With Allergen
A NA study, sponsored by University of Chicago.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01723397 is a NA study that was terminated before completion, run by University of Chicago. The registered enrollment target is 14 participants.
The verdict
NCT01723397, a NA study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The objectives of this protocol are: 1. to confirm the inhibitory effect of Nasaleze on the immediate response to nasal challenge with antigen, and 2. to show that inhibition of the immediate response to nasal challenge with antigen by Nasaleze inhibits subsequent inflammatory events.
Interventions
- DRUG Nasaleze Spray
- OTHER Placebo spray
- BIOLOGICAL Allergen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01723397
The ClinicalTrials.gov registry entry for NCT01723397 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nasaleze Spray is the first listed.
NCT01723397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01723397 about?
NCT01723397 is a clinical study titled "Effect of Nasaleze on Nasal Challenge With Allergen". The objectives of this protocol are: 1. to confirm the inhibitory effect of Nasaleze on the immediate response to nasal challenge with antigen, and 2. to show that inhibition of the immediate response to nasal challenge with antigen by Nasaleze inhibits subsequent inflammatory events.
What is the current status of trial NCT01723397?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2012-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01723397?
The interventions under investigation include: Nasaleze Spray (DRUG), Placebo spray (OTHER), Allergen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01723397?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.